Asset Details
Do you wish to reserve the book?
Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease
Do you wish to request the book?
Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease
2017
Overview
In a randomized trial involving patients with high-risk vascular disease, the cholesteryl ester transfer protein inhibitor evacetrapib had favorable effects on established lipid biomarkers but was not associated with a lower rate of cardiovascular events than placebo.
Pharmacologic reduction of the low-density lipoprotein (LDL) cholesterol level with statins substantially decreases the risks of death and complications from cardiovascular causes.
1
,
2
Considerable interest has focused on the identification of approaches that might further reduce cardiovascular-event rates among high-risk patients.
3
Epidemiologic studies have shown inverse associations between high-density lipoprotein (HDL) cholesterol levels and cardiovascular outcomes,
4
–
6
a correlation that persists despite treatment with statins.
7
Nevertheless, therapeutic interventions that raise the HDL cholesterol level have not been shown to reduce cardiovascular risk.
Cholesteryl ester transfer protein (CETP) modulates the transfer of esterified cholesterol from HDL to apolipoprotein B–containing lipoproteins.
8
Two . . .
Publisher
Massachusetts Medical Society
Subject
/ Anticholesteremic Agents - adverse effects
/ Anticholesteremic Agents - therapeutic use
/ Benzodiazepines - adverse effects
/ Benzodiazepines - therapeutic use
/ Cardiovascular Diseases - blood
/ Cardiovascular Diseases - drug therapy
/ Cardiovascular Diseases - prevention & control
/ Cholesterol Ester Transfer Proteins - antagonists & inhibitors
/ Diabetes Mellitus - drug therapy
/ Female
/ Humans
/ Intracranial Arteriosclerosis - drug therapy
/ Male
/ Myocardial Ischemia - drug therapy
/ Peripheral Vascular Diseases - drug therapy
/ Risk
/ Statins
/ Stroke
